Infant acute lymphoblastic leukemia: Lessons learned and future directions
Current Hematologic Malignancy Reports , Volume 4 - Issue 3 p. 167- 174
Compared with acute lymphoblastic leukemia (ALL) in older children, ALL in infants has a dismal outcome because rearrangements of the mixed-lineage leukemia (MLL) gene occur in about 80% of these patients, leading to an aggressive type of leukemia. With most recent therapies, about 50% long-term event-free survival is achieved, but early bone marrow relapse remains a major problem. Early intensification of chemotherapy and new innovative therapies are necessary to improve outcome. Bone marrow transplantation should be limited to a small subset of well-recognized ALL patients with a very poor prognosis. New genetic and epigenetic insights into the biology of MLL-rearranged ALL suggest new possibilities for therapies.
|Current Hematologic Malignancy Reports|
|Organisation||Erasmus MC: University Medical Center Rotterdam|
Pieters, R. (2009). Infant acute lymphoblastic leukemia: Lessons learned and future directions. Current Hematologic Malignancy Reports (Vol. 4, pp. 167–174). doi:10.1007/s11899-009-0023-4